anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain the subject medicine, having both strong immunopotentiating and proliferation inhibiting actions on a cancerous cell together, composed of a hot water extract from a rhizome of Polygonum sachalinense Fr. Schm. and useful as a potentiating substance for anticancer actions without deteriorating the activity by the enzymic hydrolysis even in oral administration. CONSTITUTION:This immunopotentiator comprises a hot water extract separated from a rhizome of Polgonum sachalinense Fr. Schm. or a precipitated substance of the hot water extract with a 80% ethanol as an active ingredient. The extract is obtained by crushing, e.g. the rhizome of the Polygonum sachalinense Fr. Schm., extracting the crushed rhizome with hot water at >=80 deg.C for 30min, then filtering, concentrating and freeze-drying the prepared extract solution.
The invention relates to a magnetic solid "dextran-MLDH-fluorouracil" liposome. The liposome is characterized in that: dextran-MLDH-fluorouracil is taken as the drug carrier, soya lecithin and cholesterol are taken as the raw materials, then the dextran-MLDH-fluorouracil liposome is prepared through the film-dispersion method, the reverse-evaporating method or the ethanol-injection method, mannitol is added into the liposome and then subjected to a freeze-sublimation treatment, and finally the product is obtained. The liposome completely maintains the crystal structure and morphology features of DMF, and has a prominent "lipid bilayer-DMF" core-shell structure characteristic and stable properties. The product is water-soluble solid magnetic liposome, and has the advantages of typical in-vitro controlled releasing performance, sensitive magnetic responsiveness, excellent cancer cell proliferation activity inhibiting ability and special and long in-vivo drug process. The invention provides an effect method for preserving DMF liposome. The method is suitable for preparation and curing preservation of magnetic drug liposome, which takes magnetic layered compound hydroxide MLDH as the carrier, has the processing advantages of low cost and simple preparation, and has the characteristics of integration of magnetic targeting and controlled releasing functions, long and durative effects, stable curative effects, and convenient storage and transportation.
Patients receive leflunomide PO QD on days 1-14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive SOC.
The cloning, sequencing and expression of a novel receptor tyrosine kinase, termed tie, is described. The tie precursor comprises 1138 amino acid residues, about 1117 residues of which comprise the mature tie. The tie extracellular domain contains distinct stretches of amino acid sequence having features of the imunoglobulin, epidermal growth factor and fibronectin type III repeat protein families. Alternative splicing creates variants of tie which lack one of the epidermal growth factor homology domains. A specific tyrosine phosphorylated 117 kD glycoprotein is detected by specific tie-antisera from cultured cells expressing the tie gene. The tie mRNA is expressed in cultured endothelial cells as well as in a few tumor cell lines. In situ hybridization of human fetal and mouse embryonic tissues shows specific expression in endothelial cells of blood vessels. The tie DNAs and polypeptides of the invention may be useful in the diagnosis and treatment of certain diseases involving endothelial cells and their tie receptor such as neoplastic diseases involving tumor angiogenesis, wound healing, thromboembolic diseases, atherosclerosis and inflammatory diseases.
Abuse and Dependence

Butalbital: Barbiturates may be habit-forming: Tolerance, psychological dependence, and physical dependence may occur especially following prolonged use of high doses of barbiturates. The average daily dose for the barbiturate addict is usually about 1500 mg. As tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication increases; tolerance to a fatal dosage, however, does not increase more than two-fold. As this occurs, the margin between an intoxication dosage and fatal dosage becomes smaller. The lethal dose of a barbiturate is far less if alcohol is also ingested. Major withdrawal symptoms (convulsions and delirium) may occur within 16 hours and last up to 5 days after abrupt cessation of these drugs. Intensity of withdrawal symptoms gradually declines over a period of approximately 15 days. Treatment of barbiturate dependence consists of cautious and gradual withdrawal of the drug. Barbiturate-dependent patients can be withdrawn by using a number of different withdrawal regimens. One method involves initiating treatment at the patient’s regular dosage level and gradually decreasing the daily dosage as tolerated by the patient.

Butalbital Caffeine Acetaminophen 50/325/40 Tablet Permanent Link: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a26775c2-cafb-4b13-99ac-d4e8248265fb
Successful treatment of hypertension with single medications is very rare. On average successful treatment requires more than 2 medications. These medications work by different methods. One of the ideas behind the use of combinations of medication for hypertension is that benefits are additive. There are unresolved questions about whether the observed benefits are simply related to effective treatment of hypertension, or whether some of the medications have special benefits independent of blood pressure lowering. Each of these contentions has been justified by clinical trials. However these trials have in common the flaw that hypertension is either not effectively controlled in all the treated subjects, or the magnitude of blood pressure change after treatment is different in the groups compared. The result of one of the largest blood pressure clinical trials called ALLHAT trial has recently fuelled this debate. The ALLHAT trial which utilized only subjective symptoms and signs of heart failure, called the FRAMINGHAM score, to determine who has abnormal heart function, implied that diuretics (water pills) were superior to the newer drugs in reducing the frequency of abnormal heart function. This study shared the flaw of previous trials in not having equal blood pressure lowering in the groups. Nevertheless it provided some evidence that argued against the notion that newer drugs were better than older drugs like diuretics. Shortly after the publication of ALLHAT, another trial called ANBP was published showing that the group of drugs that was least effective in ALLHAT was superior to diuretics in preventing important cardiovascular outcomes. Hence, it is not currently clear that there are differences between various drug combinations, if effective and equal blood pressure lowering is achieved. Another finding that may have confounded clinical trials that rely on subjective scores of heart dysfunction such as the ALLHAT, is that a significant proportion of subjects with advanced heart disease are unaware of their heart problem and hence will probably not seek attention. This raises the concern that the true frequency of abnormal heart function might not have been reported in those studies. Using more modern tools such as Echocardiography, a more complete assessment of heart dysfunction can be obtained. In addition objective tests of heart function such as the 6-minute walk distance could yield a more reliable assessment of any worsening or improvement in heart function if performed serially in treated subjects. In view of the above discussion, only a study in which hypertension is effectively and similarly controlled could be used to answer the questions regarding different effects of various drug combinations. Such is this study proposed.
A polysaccharide or lipopolysaccharide which has antigenic activity is extracted from a microorganism, as defined below, which contains it, by treatment with a liquid dialkyl sulphoxide, with subsequent isolation of the polysaccharide or lipopolysaccharide from the dialkyl sulphoxide solution obtained. Microorganisms include all bacteria, yeasts, fungi, protozoa and higher parasites, but excludes viruses.  Dimethyl sulphoxide is preferred, and the resulting isolation may be effected by fractional precipitation.ALSO:Polysaccharides and lipopolysaccharides having antigenic activity are extracted by means of dimethyl sulphoxide from micro-organisms (except viruses).  In the Examples polysaccharides are extracted from the following microorganisms:  Trichomonas vaginalis (Ex. 1), Candida albicans (Ex. 2), Mycobacteria tuberculosis (the solution also containing 0.1% of a polyethylenesorbitolmonooleate detergent) (Ex. 3), Saccharomyces cerevisiae (Bear yeast) (Ex. 4).  Extraction is effected at 60-100 DEG C.  The active agent is isolated from the solvent by fractional precipitation.  The antigenic material may be used in injectable compositions in the form of an aqueous-dimethyl sulphoxide solution, which may contain a surface active agent, and may further be emulsified with paraffin oil.
Spoken language development after pediatric cochlear implantation requires rapid and efficient processing of novel, degraded auditory signals and linguistic information. These demands for rapid adaptation tax the information processing speed ability of children who receive cochlear implants. This study investigated the association of speed of information processing ability with spoken language outcomes after cochlear implantation in prelingually deaf children aged 4-6 years. Two domain-general (visual, non-linguistic) speed of information processing measures were administered to 21 preschool-aged children with cochlear implants and 23 normal-hearing peers. Measures of speech recognition, language (vocabulary and comprehension), nonverbal intelligence, and executive functioning skills were also obtained from each participant. Speed of information processing was positively associated with speech recognition and language skills in preschool-aged children with cochlear implants but not in normal-hearing peers. This association remained significant after controlling for hearing group, age, nonverbal intelligence, and executive functioning skills. These findings are consistent with models suggesting that domain-general, fast-efficient information processing speed underlies adaptation to speech perception and language learning following implantation. Assessment and intervention strategies targeting speed of information processing may provide better understanding and development of speech-language skills after cochlear implantation.
The rotor arm (15) is located in the base of the silo and is manufactured of spring steel. The arm is terminated at its outer end by means of a hook (35) which is able to scrape along the edge of the silo. A tensioning device (57) is joined by a cable (55) to the end of the rotor. The tensioning device is fitted with two limit stops (58, 59). A secondary cable follows the contour of the rotor and is maintained under tension all the time the rotor is operating. This cable is located by blocs. The rotor is able to sweep the entire base of the silo for emptying.
UNLABELLED: Equine herpesvirus type 1 (EHV-1) is one of the most prevalent respiratory pathogens in horses with a high impact on animal health worldwide. Entry of the virus into epithelial cells of the upper respiratory tract and rapid local viral replication is followed by infection of local lymphoid tissues leading to cell-associated viremia and disease progression. Pre-existing mucosal immunity has previously been shown to reduce viral shedding and prevent viremia, consequently limiting severe disease manifestations. Here, nasopharyngeal transcriptomic profiling was used to identify differentially expressed genes following EHV-1 challenge in horses with different EHV-1 immune statuses. Immune horses (n = 4) did neither develop clinical disease nor viremia and did not shed virus after experimental infection, while non-immune horses (n = 4) did all the above. RNA sequencing was performed on nasopharyngeal samples pre- and 24 hours post-infection (24hpi). At 24hpi, 109 and 44 genes were upregulated in immune horses and non-immune horses, respectively, and three genes were explored in further detail. Antileukoproteinase (SLPI) gene expression increased 2.1-fold within 24 hours in immune horses in concert with protein secretion. Interferon (IFN)-induced proteins with tetratricopeptide repeats 2 (IFIT2) and 3 (IFIT3) were upregulated in non-immune horses, corresponding with nasal IFN-α secretion and viral replication. By contrast, neither IFIT expression nor IFN-α secretion was induced by EHV-1 infection of immune horses. Transcriptomic profiling offered a tool to identify, for the first time, the role of SLPI in innate immunity against EHV-1, and further emphasized the central role of the type I IFN response in the anti-viral defense of non-immune horses.
IMPORTANCE: Equine herpesvirus type 1 (EHV-1) remains a considerable concern in the equine industry, with yearly outbreaks resulting in morbidity, mortality, and economic losses. In addition to its importance in equine health, EHV-1 is a respiratory pathogen and an alphaherpesvirus, and it may serve as a model for other viruses with similar pathogenicity or phylogeny. Large animal models allow the collection of high-volume samples longitudinally, permitting in-depth investigation of immunological processes. This study was performed on bio-banked nasopharyngeal samples from an EHV-1 infection experiment, where clinical outcomes had previously been determined. Matched nucleic acid and protein samples throughout infection permitted longitudinal quantification of the protein or related proteins of selected differentially expressed genes detected during the transcriptomic screen. The results of this manuscript identified novel innate immune pathways of the upper respiratory tract during the first 24 hours of EHV-1 infection, offering a first look at the components of early mucosal immunity that are indicative of protection.
Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
BACKGROUND: Undifferentiated pleomorphic sarcoma (UPS) is a relatively rare but aggressive neoplasm. We sought to utilize a multi-institutional US cohort of sarcoma patients to examine predictors of survival and recurrence patterns after resection of UPS.
METHODS: From 2000 to 2016, patients with primary UPS undergoing curative-intent surgical resection at seven academic institutions were retrospectively reviewed. Epidemiologic and clinicopathologic factors were reviewed by site of origin. Overall survival (OS), recurrence-free survival (RFS), time-to-locoregional (TTLR), time-to-distant recurrence (TTDR), and patterns of recurrence were analyzed.
RESULTS: Of the 534 UPS patients identified, 53% were female, with a median age of 60 and median tumor size of 8.5 cm. The median OS, RFS, TTLR, and TTDR for the entire cohort were 109, 49, 86, and 46 months, respectively. There were no differences in these survival outcomes between extremity and truncal UPS. Compared with truncal, extremity UPS were more commonly amenable to R0 resection (87% vs. 75%, p = 0.017) and less commonly associated with lymph node metastasis (1% vs. 6%, p = 0.031). R0 resection and radiation treatment, but not site of origin (extremity vs. trunk) were independent predictors of OS and RFS. TTLR recurrence was shorter for UPS resected with a positive margin and for tumors not treated with radiation.
CONCLUSION: For patients with resected extremity and truncal UPS, tumor size >5 cm and positive resection margin are associated with worse survival OS and RFS, irrespectively the site of origin. R0 surgical resection and radiation treatment may help improve these survival outcomes.
PURPOSE:To obtain a granular preparation readily dispersible into water, having excellent suspension stability by granulating finely powdery ebselen with a hydrophilic polymer. CONSTITUTION:10-50wt.% ebselen having <=50mum average particle diameter is blended with 0.5-100wt.% based on ebselen of a hydrophilic polymer (e.g. hydroxypropylmethyl cellulose) and optionally another additive properly and pharmaceutically manufactured into a state of granule having usually 50-2,000mum particle diameter by fluidized bed granulation method. The preparation is excellent as a preparation for tube administration by Margen tube. Since a medicine or a solution of medicine does not remain in the tube after administration, a dose is precise. The granular preparation is readily made into an aqueous preparation by adding water. The granular preparation can be given to a patient of subarchnoid hemorrhage, etc., incapable of taking an oral agent by oneself.
Physical activity is essential to interrupt the cycle of deconditioning associated with chronic kidney disease (CKD). However, access to targeted physical activity interventions remain under-supported due to limited funding and specialised staff. Digital interventions may address some of these factors. This systematic review sought to examine the evidence base of digital interventions focused on promoting physical activity or exercise and their effect on health outcomes for people living with CKD. Electronic databases (PubMed, CINAHL, Embase, Cochrane) were searched from 1 January 2000 to 1 December 2023. Interventions (smartphone applications, activity trackers, websites) for adults with CKD (any stage, including transplant) which promoted physical activity or exercise were included. Study quality was assessed, and a narrative synthesis was conducted. Of the 4057 records identified, eight studies (five randomised controlled trials, three single-arm studies) were included, comprising 550 participants. Duration ranged from 12-weeks to 1-year. The findings indicated acceptability and feasibility were high, with small cohort numbers and high risk of bias. There were inconsistent measures of physical activity levels, self-efficacy, body composition, physical function, and psychological outcomes which resulted in no apparent effects of digital interventions on these domains. Data were insufficient for meta-analysis. The evidence for digital interventions to promote physical activity and exercise for people living with CKD is limited. Despite popularity, there is little evidence that current digital interventions yield the effects expected from traditional face-to-face interventions. However, 14 registered trials were identified which may strengthen the evidence-base.
This study will be completed in two phases. In the first phase, the participants included in the study will be evaluated first by tele-assessment. One hour later, all assessments will be repeated face-to-face procedures by the researchers; thus, the validity of the tele-assessment method will be determined. Before the tele-assessment, participants will be informed about having a chair whose floor-to-seat height is 48 cm and tape measure. In the second phase of the study, to determine the reliability of the tele-assessment method, all tests will be applied to the previously tested participant by the same researcher one week later and at the same time of the day using only the tele-assessment method.
The invention relates to a non-living vaccine which contains antigens which stimulate the production in the host of antibodies and which gives protection, when administered by injection, against diseases caused by nematodes which are pathogenic to vertebrates.  Cleaned third-stage infective larv  collected from the f ces of infected animals are immersed in a medium which induces exsheathment, for example an aqueous solution of sodium hypochlorite and sodium chloride.  When exsheathment has taken place, the larv  are separated from the solution which is reserved.  The larv  are then treated with an antimicrobial agent, e.g. a mixture of penicillin and streptomycin, to reduce the possibility of bacterial or other contamination and cultured in a sterile balanced salt solution containing nutrient material, e.g. extract of liver, casein hydrolysis products, to permit their development into the histotrophic stages.  Incubation is at 37 DEG  C. with oxygenation. The culture medium and its contained larv  is then frozen and dried by freeze-drying.  The reserved solution from the exsheathment process, first treated to remove any unwanted inorganic ions may be added before drying.  The dried antigenic material thus obtained is suspended in a sterile aqueous vehicle before injection.  Specified nematode larv  are Dictyocaulus viviparus, Haemonehus contortus, Astertagia astertagi, Strongylus vulgaris, Trichostrongylus axei, Strongyloides papillosus, Astertagia circumeincta and Trichostrongylus colubriformis.  Specification 819,830 is referred to.
The objective of the Taste Perception Study is to assess variations in oral sensations in younger (18-49 years; n=35) relative to older (50-85 years; n=35) subjects, and determine the association between variations in oral sensations and measures of chronic disease risk factors, body composition, habitual dietary intake and selected genes mediating sensory perception and dietary behaviors. Subjects who are participating in the Glycemic Index study (IRB #7196) will be asked for voluntarily participation in the proposed study. These volunteers will undergo 1-2 hours of standardized testing. These tests will involve tasting or smelling certain foods/beverages or ingredients in foods/beverages and rating the degree of liking/disliking, intensity and flavor or odor using a validated general Labeled magnitude scale. Volunteers will also be asked to complete a food preference survey and eating inventory questionnaire, as well as provide a DNA sample from a cheek swab or blood sample. These data will then be merged with the measures of chronic disease risk factors, body composition and habitual dietary intake data generated from the Glycemic index study in order to better understand if variations in oral sensations influence food preferences and patterns and subsequently chronic disease risk.
Patients receive niclosamide PO TID and enzalutamide PO daily. Treatment continues for 28 days in the absence of disease progression or unacceptable toxicity.
Preclinical studies in mice have established that several members of the Als family of proteins induce a protective immune response in mice and allow high survival rates following challenge with highly virulent doses of either Candida or S. aureus. Als3 (the antigen in the NDV-3 investigational vaccine) is the most effective member of the Als protein family in protecting mice from challenge with either Candida or S. aureus. This Phase I study will evaluate the safety and immunogenicity of a two doses administered 6 months apart of NDV-3 vaccine at two dose levels. At least 40 subjects will be enrolled in the study in two groups of approximately 20 subjects each. Each group will be randomized so that 15 will receive NDV-3 vaccine and 5 will receive placebo. All injections will be administered intramuscularly. One group will receive a low dose of NDV-3 and the other a ten-fold higher dose. Subjects will have follow-up visits to assess the safety, tolerability and immune responses at days 3, 7, 14, 28, 90 and 180 after the first vaccination to compare to baseline levels and at days 7, 14 and 90 after the second vaccination.